Control of intestinal inflammation by glycosylation-dependent lectin-driven immunoregulatory circuits.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 34144987.
- Also identified by DOI 10.1126/sciadv.abf8630 and PMC identifier 8213219.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Diverse immunoregulatory circuits operate to preserve intestinal homeostasis and prevent inflammation. Galectin-1 (Gal1), a β-galactoside-binding protein, promotes homeostasis by reprogramming innate and adaptive immunity. Here, we identify a glycosylation-dependent "on-off" circuit driven by Gal1 and its glycosylated ligands that controls intestinal immunopathology by targeting activated CD8<sup>+</sup> T cells and shaping the cytokine profile. In patients with inflammatory bowel disease (IBD), augmented Gal1 was associated with dysregulated expression of core 2 β6-<i>N</i>-acetylglucosaminyltransferase 1 (<i>C2GNT1</i>) and α(2,6)-sialyltransferase 1 (<i>ST6GAL1</i>), glycosyltransferases responsible for creating or masking Gal1 ligands. Mice lacking Gal1 exhibited exacerbated colitis and augmented mucosal CD8<sup>+</sup> T cell activation in response to 2,4,6-trinitrobenzenesulfonic acid; this phenotype was partially ameliorated by treatment with recombinant Gal1. While <i>C2gnt1<sup>-/-</sup></i> mice exhibited aggravated colitis, <i>St6gal1<sup>-/-</sup></i> mice showed attenuated inflammation. These effects were associated with intrinsic T cell glycosylation. Thus, Gal1 and its glycosylated ligands act to preserve intestinal homeostasis by recalibrating T cell immunity.